MEASURING PREFERENCES FOR SCHIZOPHRENIA OUTCOMES

衡量精神分裂症结果的偏好

• 批准号: 2250800
• 负责人: WILLIAM A HARGREAVES
• 金额: $ 15.3万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-05-01 至 1997-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2250800
• 关键词: abnormal involuntary movement; data collection methodology /evaluation; decision making; drug adverse effect; employment /unemployment; family; hallucinations; housing; human population study; human subject; human therapy evaluation; preference; psychiatrist; psychometrics; questionnaires; schizophrenia; sign /symptom; social adjustment; social support network

Determining the effectiveness of schizophrenia treatments requires aggregate measures that reflect the relative importance of schizophrenia's multiple outcome domains. A lack of understanding of the relative importance of various domains prevents meaningful aggregation of outcome measures and limits inferences drawn from treatment research. This study is designed to develop and apply methods for determining the importance of schizophrenia treatment outcomes by adapting preference assessment methods used in general health status research. The first of two study phases is devoted to method development. Four preference assessment methods (category rating, time trade-off, paired comparison and direct importance rating) used successfully in prior health status research will be evaluated in two expert groups, one comprised of clinicians providing schizophrenia treatment and one of persons with schizophrenia. In the second phase, the two preference assessment methods found to be most feasible, valid and reliable in the method development phase will be compared in a randomized, factorial design including 4 stakeholder groups directly and indirectly involved in schizophrenia treatment (persons with schizophrenia, clinicians providing schizophrenia treatment, family members of persons with schizophrenia and members of the general public). This method and group comparison will (1) determine which methods perform comparably across stakeholder groups in terms of feasibility, validity, reliability and efficiency, (2) determine whether stakeholder group membership or other demographic characteristics affect preferences for treatment outcomes, (3) identify methods best suited for use in future studies of schizophrenia treatment outcome, (4) generate preference weights for key outcomes which can be applied retrospectively to existing research findings as well as in future studies where preference assessment is not practical. Study findings will also inform the study of other serious mental disorders and help to resolve prevailing controversies about the importance of method and stakeholder group differences in health status preference assessment.

确定精神分裂治疗的有效性需要 反映精神分裂症相对重要性的综合措施 多个结果域。 对亲戚的理解不足 各个领域的重要性阻止有意义的结果聚集 从治疗研究中得出的措施和限制。这项研究 旨在开发和应用方法来确定 通过调整偏好评估方法的精神分裂症治疗结果 用于一般健康状况研究。 两个研究阶段中的第一个专门用于方法开发。四个 偏好评估方法（类别等级，时间权衡，配对 比较和直接重要性等级）成功用于先前的健康 地位研究将在两个专家小组中进行评估，一个由 提供精神分裂症治疗的临床医生，其中一个 精神分裂症。 在第二阶段，发现两种偏好评估方法是 在方法开发阶段，最可行，有效和可靠的是 在一个随机的阶乘设计中进行比较，包括4个利益相关者群体 直接和间接参与精神分裂症治疗（患有 精神分裂症，提供精神分裂症治疗的临床医生，家庭 精神分裂症和公众成员的成员）。 此方法和组比较将（1）确定哪些方法执行 就可行性，有效性， 可靠性和效率，（2）确定利益相关者群体是否 成员资格或其他人口特征会影响对的偏好 治疗结果，（3）确定最适合将来使用的方法 精神分裂症治疗结果的研究，（4）产生偏好 关键结果的权重，可以追溯地应用于现有 研究结果以及未来的偏好评估的研究 不实用。研究结果还将告知其他 严重的精神障碍并有助于解决盛行的争议 关于方法和利益相关者群体在健康方面的重要性 状态偏好评估。